A multicenter U.S. trial studied the ProCol ^® vascular access graft in 226 challenging patients with 1-6 prior failed grafts. Thirty-six percent of the patients had already failed at least three synthetic grafts. Cumulative patency at three years was 54% for ProCol ^®, compared to 10% for the same patient's most recent synthetic graft prior to receiving ProCol ^®.

Incidents of complications were significantly less with ProCol ^® compared to ePTFE grafts, particularly thrombosis and infection.

Since the ProCol ^® Vascular Bioprosthesis recieved approval from the U.S. Food and Drug Administration in July, 2003 Procol has been implated in dialysis patients across the United States

ProCol® Vascular Bioprosthesis – Clinical Investigation Sites:

• Cedars Medical Center, Miami, Florida
• Duke University Medical Center, Durham, NC
• Eastern Virginia Medical Center, Norfolk, VA
• University of Southern California School of Medicine, Los Angeles, CA
• University of California Irvine Medical Center, Orange, CA
• University of Miami, School of Medicine, Miami, FL